Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (age 18-75) with chronic HBV (positive for serum hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months) prior to baseline~* Anti-HBV treatment-naive adults; adults who have taken oral anti-HBV nucleoside therapy with the last dose ≥ 24 weeks prior to screening are also eligible.~* Positive or negative for hepatitis B e antigen (HBeAg)~* HBV DNA ≥ 20,000 IU/ml (HBeAg-positive participants) and ≥ 2,000 IU/ml (HBeAg-negative participants)~* Alanine aminotransferase (ALT) \> 54 U/L and ≤ 400 U/L for men and \> 36 U/L and ≤ 300 U/L for women~* Creatinine clearance ≥ 70 mL/min~* Negative serum pregnancy test for females of childbearing potential~* Sexually active females of childbearing potential must agree to use a protocol-recommended method of contraception throughout the study and for 30 days following the last dose of study medication~* Lactating females must agree to discontinue nursing before initiation of study investigational medicinal product~Exclusion Criteria:~* Known bridging fibrosis or cirrhosis and/or decompensated liver disease~* Evidence of hepatocellular carcinoma~* Significant kidney, heart, lung, neurological, autoimmune disease, or bone disease (eg, osteomalacia,chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis, multiple bone fractures)~* Absolute neutrophil count \< 1,500/mm\^3, platelet \< 100,000/mm\^3, hemoglobin \< 10 g/dL (female) or \< 11 g/dL (male)~* History of severe depression or severe psychiatric disease~* Thyroid dysfunction~* Coinfection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TDF+Peg-IFN 48 Weeks (Type: EXPERIMENTAL): TDF plus Peg-IFN for 48 weeks
- TDF 48 Weeks + Peg-IFN 16 Weeks (Type: EXPERIMENTAL): TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
- TDF 120 Weeks (Type: ACTIVE_COMPARATOR): TDF monotherapy for 120 weeks
- Peg-IFN 48 Weeks (Type: ACTIVE_COMPARATOR): Peg-IFN monotherapy for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).